Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: A retrospective longitudinal survey using data from electronic medical records

Cardiovascular Diabetology

Volumn 9, Issue , 2010, Pages

  Nishida, Yayoi ^a   Takahashi, Yasuo ^a   Nakayama, Tomohiro ^a   Soma, Masayoshi ^a   Kitamura, Noboru ^a   Asai, Satoshi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANDESARTAN HEXETIL; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; CANDESARTAN; LIPID; TETRAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE DURATION; DRUG EFFECT; ELECTRONIC MEDICAL RECORD; FEMALE; HEALTH SURVEY; HUMAN; HYPERTENSION; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; RETROSPECTIVE STUDY; SCORING SYSTEM; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; DYSLIPIDEMIA; LONGITUDINAL STUDY; MIDDLE AGED; STATISTICS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; DYSLIPIDEMIAS; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; HYPERTENSION; LIPIDS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TETRAZOLES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955549185     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-9-38     Document Type: Article

References (27)

1. Doggrell SA. Telmisartan - killing two birds with one stone. Expert Opin Pharmacother 2004, 5:2397-2400. 10.1517/14656566.5.11.2397, 15500387.
2. Kitamura N, Takahashi Y, Yamadate S, Asai S. Angiotensin II receptor blockers decreased blood glucose levels: a longitudinal survey using data from electronic medical records. Cardiovasc Diabetol 2007, 6:26. 10.1186/1475-2840-6-26, 2098751, 17903269.
3. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A, . SCOPE Study Group The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003, 21:875-886. 10.1097/00004872-200305000-00011, 12714861, SCOPE Study Group.
4. Schrader J, Lüders S, Kulschewski A, Berger J, Zidek W, Treib J, Einhäupl K, Diener HC, Dominiak P, . Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003, 34:1699-1703. 10.1161/01.STR.0000075777.18006.89, 12817109, Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group.
5. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S, . CHARM Investigators and Committees Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003, 362:759-766. 10.1016/S0140-6736(03)14282-1, 13678868, CHARM Investigators and Committees.
6. Zorad S, Dou JT, Benicky J, Hutanu D, Tybitanclova K, Zhou J, Saavedra JM. Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma. Eur J Pharmacol 2006, 552:112-122. 10.1016/j.ejphar.2006.08.062, 1764497, 17064684.
7. Kyvelou SM, Vyssoulis GP, Karpanou EA, Adamopoulos DN, Zervoudaki AI, Pietri PG, Stefanadis CI. Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial. Hellenic J Cardiol 2006, 47:21-28.
8. Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi M, Nanjo K, Sasaki A, Seino Y, Ito C, Shima K, Nonaka K, Kadowaki T, . Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract 2002, 55:65-85. 10.1016/S0168-8227(01)00365-5, 11755481, Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus.
9. Johnson ML, Crown W, Martin BC, Dormuth CR, Siebert U. Good research practices for comparative effectiveness research: analytic method to improve casual inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR good research practices for retrospective database analysis task force report-part III. Value Health 2009, 12:1062-1073. 10.1111/j.1524-4733.2009.00602.x, 19793071.
10. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983, 70:41-55.
11. Kang DH, Park SJ, Rim JH, Yun SC, Kim DH, Song JM, Choo SJ, Park SW, Song JK, Lee JW, Park PW. Early surgery versus conventional treatment in asymptomatic very severe aortic stenosis. Circulation 2010, 121:1502-1509. 10.1161/CIRCULATIONAHA.109.909903, 20308614.
12. Hannan EL, Racz MJ, Walford G, Jones RH, Ryan TJ, Bennett E, Culliford AT, Isom OW, Gold JP, Rose EA. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N Engl J Med 2005, 352:2174-2183. 10.1056/NEJMoa040316, 15917382.
13. Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med 2002, 346:822-9. 10.1056/NEJMsa003087, 11893794.
14. Imbens GW. The role of the propensity score in estimating dose-response functions. Biometrika 2000, 87:706-710.
15. Patel BV, Leslie RS, Thiebaud P, Nichol MB, Tang SS, Solomon H, Honda D, Foody JM. Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen. Vasc Health Risk Manag 2008, 4:673-681. 2515427, 18827917.
16. Linden A, Adams JL. Evaluation health management programmes over time: application of propensity score-based weighting to longitudinal data. J Eval Clin Pract 2010, 16:180-185. 10.1111/j.1365-2753.2009.01361.x, 20367830.
17. Leslie S, Thiebaud P. Using propensity score to adjust for treatment selection bias. SAS Global forum 2007 paper 184-2007 , http://www2.sas.com/proceedings/forum2007/184-2007.pdf
18. D'Agostino R. Tutorial on Biostatistics: Propensity Score Methods for Bias Reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998, 17:2265-2281. 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B, 9802183.
19. Bramlage P, Hasford J. Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment--a review. Cardiovasc Diabetol 2009, 8:18. 10.1186/1475-2840-8-18, 2669450, 19327149.
20. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, Yoshida D, Shimamoto K. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003, 42:76-81. 10.1161/01.HYP.0000078490.59735.6E, 12796280.
21. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Koh Y, Shin EK. Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. Int J Cardiol 2010, 140:73-81. 10.1016/j.ijcard.2008.11.017, 2862263, 19059660.
22. Trenkwalder P, Dahl K, Lehtovirta M, Mulder H. Antihypertensive treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in patients with mild hypertension and type II diabetes. Blood Press 1998, 7:170-175. 10.1080/080370598437385, 9758087.
23. Derosa G, Cicero AF, Ciccarelli L, Fogari R. A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus. Clin Ther 2003, 25:1006-1021.
24. National Cholesterol Education Program (NCEP) Expert Panel on Detection and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421. National Cholesterol Education Program (NCEP) Expert Panel on Detection and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
25. Sutherland WH, Temple WA, Nye ER, Herbison GP. Adiposity, lipids, alcohol consumption, smoking, and gender. Am J Clin Nutr 1980, 33:2581-2587.
26. The writing group for PEPI trial Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995, 273:199-208. 10.1001/jama.273.3.199, 7807658, The writing group for PEPI trial.
27. Arnold RG, Kotsanos JG. Panel 3: methodological issues in conducting pharmacoeconomic evaluations--retrospective and claims database studies. Value Health 1999, 2:82-87. 10.1046/j.1524-4733.1999.02204.x, 16674338.